FDA Grants Breakthrough Therapy Designation to JBS-003 for Guiding De-escalated Radiotherapy in HPV-Positive Oropharyngeal Cancer

On September 1, Juniper Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its hypoxia tracer JBS-003. The product, 18F-Fluoromisonidazole (FMISO), is intended to identify tumor hypoxia and guide de-escalated radiotherapy in patients with HPV-positive oropharyngeal cancer (OPC).

JBS-003 is licensed from Memorial Sloan Kettering Cancer Center (MSK). According to information released by the company, the tracer is based on F-MISO PET molecular imaging technology and can visualize specific hypoxic features within tumors. Tumor hypoxia is considered to be associated with radioresistance; by imaging hypoxic regions, clinicians can stratify patients by risk and develop more targeted radiotherapy regimens for individual patients.

Currently, patients with HPV-positive oropharyngeal cancer typically receive standard-intensity radiotherapy. Data indicate that such regimens may lead to severe and long-term complications, including risks associated with osteoradionecrosis, significant weight loss, and impaired quality of life. Juniper Biosciences stated that relevant studies show approximately 80% of these patients do not present with hypoxic tumors, suggesting that radiation dose could potentially be reduced while maintaining disease control, lowering the standard absorbed dose from 70 Gy to 30 Gy.

FDA Breakthrough Therapy Designation applies to programs intended to treat serious conditions where preliminary clinical evidence indicates substantial improvement over existing therapies on clinically significant endpoints. The designation for JBS-003 is supported by early investigator-initiated hypoxia imaging experience at MSK, as well as evidence accumulated from Juniper Biosciences' ongoing clinical programs. The designation also provides for more intensive FDA guidance on the development program and eligibility for rolling review and priority review.

The ongoing Phase 3 clinical trial of JBS-003 (NCT06563479) is a randomized, double-blind study designed to evaluate a FMISO-screening-based de-escalated radiotherapy regimen. Patients in the personalized treatment arm will undergo an FMISO scan during the second week of treatment; if the result indicates no hypoxia, they may receive a reduced radiation dose of 30 Gy; if hypoxia is present, they will continue with the standard 70 Gy treatment. The trial is expected to complete its primary endpoint in early 2028.

Juniper Biosciences stated that it will work with the FDA to establish a registration pathway for JBS-003. MSK radiation oncologist Nancy Y. Lee expressed anticipation for the completion of the Phase 3 trial and the acquisition of key evidence supporting potential FDA approval. The disclosure also noted that MSK and Nancy Y. Lee hold equity interests in Juniper Biosciences.